Ekf Diagnostics Holdings Plc · LSE:EKF
Ekf Diagnostics — Q2 2025 Earnings Presentation
20 slides from Ekf Diagnostics's earnings presentation, Sep 16, 2025
Slide 1: EKF Diagnostics Holdings plc Interim Results Presentation
EKF Diagnostics Holdings plc Interim Results Presentation Period Ended 30 June 2025 ekfdiagnostics.com
Slide 2: The EKF Team
The EKF Team Julian Baines Gavin Jones Stephen Young Executive Chair Chief Executive Officer Chief Financial Officer Experienced CEO and Exec Chair Previously Chief Product Officer for Experienced Finance Director & CFO with proven industry acumen EKF Diagnostics Holdings plc AIM experience across m
Slide 3: Financial Highlights
Financial Highlights • Revenues of £25.2m (£25.8m on constant currency terms) • Gross profit of £12.7m (2024 H1: £12.1m) • Gross margin improved to 50% (2024 H1: 48%) • Adjusted EBITDA of £5.8m up 7.4% (2024 H1: £5.4m) • Profit before tax of £3.6m up 16.1% (2024 H1: £3.1m) • Net Cash generated from
Slide 4: Operational Highlights
Operational Highlights • Strategy communicated and implemented across the business to ensure clarity of vision and focus • Production capacity improvement plans initiated in key strategic growth areas within Point-of-Care delivering approximately 30% increase • β-HB up 12% (16% on consistent currenc
Slide 5: Board Expectations 2025: H1 Update
Board Expectations 2025: H1 Update Capital deployment to deliver Implement share buyback to improve 01 sustainable growth and unlock 02 earnings per share (EPS) unrealized potential Investment in Operational Excellence to increase production Utilize cash reserves to implement a progressive, ongoing
Slide 6: Five-Year Strategy: H1 Update
Five-Year Strategy: H1 Update Target 2029 Target 2029 Target 2029 Revenue: >£80m #1 Point-of-Care (POC) #1 Ketone Testing (β-HB) EBITDA: >£20m Hemoglobin Laboratory & POC Revenue target for 2025 Evaluations in US blood New product development looking to be in line with banks established, new progres
Slide 7: Five Year Strategy: Geography H1 Update
Five Year Strategy: Geography H1 Update Geographic Revenue 14,000 Americas continues to grow 12,000 3% Positive regional growth of 3% in Americas driven by continued β-HB expansion in the US, and Hematology 10,000 coming back online in Peru 8,000 EMEA opening new markets £’m 6,000 3% New contracts i
Slide 8: Five-Year Strategy: Analyzer Build H1 Update
Five-Year Strategy: Analyzer Build H1 Update Hematology analyzer build H1 2024 vs H1 2025 6000 HemoControl strong start 125% Focus has been on HemoControl in 2025 with an increase in analyzer build of 125% driven by growth in 5000 Peru, Brazil, USA, and Italy Number of analyzers 4000 DiaSpect still
Slide 9: Five-Year Strategy: Life Sciences H1 Update
Five-Year Strategy: Life Sciences H1 Update Life Sciences Active Pipeline Strong pipeline of new business $1.5m Wider pipeline of new customers at various stages of development from quotations issued through to draft agreements A Significant contract final stage Customer Pipeline B C $280k New devel
Slide 10: Outlook
Outlook • Deliver on broader pipeline of new Life Science opportunities with at least one new significant partnership in H2 2025 • Focus on ensuring the pull through of consumables aligns with the record Hematology analyzer production achieved in H1 2025 • Continue to support the strategy developmen
Slide 11: Thank You
Thank You Thank You ekfdiagnostics.com 11
Slide 12: Financial
Financial 12
Slide 13: Business Units
Business Units £ '000 2025 (H1) 2024 (H1) +/- £k Point-of-Care 15,458 15,191 267 Life Sciences 9,253 8,599 654 Other 321 667 (346) 02 Discontinued Products 207 755 (548) Total Group Revenues 25,239 25,212 27 13
Slide 14: Income Statement
Income Statement £ '000 2025 (H1) 2024 (H1) +/- £k Revenue 25,239 25,212 27 Cost of Sales (12,568) (13,150) 582 Exceptional items - 58 (58) Gross Profit 12,671 12,120 551 Gross Margin % 50% 48% 2% 02 Admin Expenses/Overheads (9,183) (9,160) (23) Exceptional items - (29) 29 Other Income 98 139 (41) 0
Slide 15: Appendices
Appendices 15
Slide 16: Non-executive Directors
Non-executive Directors Christian Rigg - Senior Independent Non-executive Director Chris Rigg is a chartered accountant who has significant executive experience at both public and private companies. He is Chief Executive Officer of PAM Group, a private equity backed healthcare business. He was forme
Slide 17: Balance Sheet – Assets
Balance Sheet – Assets £ '000 2025 (H1) 2024 +/- £k Fixed assets 21,875 24,034 (2,159) Intangible assets 28,791 28,922 (131) Investments 206 228 (22) Deferred tax 25 9 16 Inventories 7,826 7,393 433 02 Receivables 7,091 6,803 288 Corporation tax - 55 (55) Cash 16,616 14,301 2,315 03 Total assets 82,
Slide 18: Balance Sheet – Liabilities
Balance Sheet – Liabilities £ '000 2025 (H1) 2024 +/- £k Payables 6,913 6,717 196 Deferred tax liabilities 1,813 1,198 615 Corporation tax 824 618 206 02 Total creditors 9,550 8,533 1,017 Capital and reserves 71,734 72,327 (593) Minority interest 1,146 885 261 03 Total equity 72,880 73,212 (332) 18
Slide 19: Cash Flow
Cash Flow £ '000 2025 (H1) 2024 (H1) +/- £k Net cash generated from 4,920 7,865 (2,945) operating activities Net cash used in investing (938) (1,758) 820 activities Net cash used in financing (1,437) (4,070) 2,633 activities Net increase in cash and cash 2,545 2,037 508 02 equivalents Cash and cash
Slide 20: Disclaimer
Disclaimer The information contained in these slides and the accompanying oral presentation (together, the “Presentation”) has been prepared by EKF Diagnostics Holdings plc (the “Company”). The Presentation is subject to updating, completion, revision, and amendment without notice, and as such, it m
EKF Diagnostics Holdings — Q2 2025 Earnings Presentation on 6ix